High-risk Prostate Cancer
15
7
8
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
6.7%
1 terminated out of 15 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (15)
Immunotherapy Before and After Surgery
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect)
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Ga-68-PSMA-11 in High-risk Prostate Cancer